Thermo Fisher expands global footprint in North America & Europe for sterile drug product development and commercial manufacturing: Waltham, Massachusetts Friday, December 11, 202 ...

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...

Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC: Ingelheim, Germany Monday, Oc ...

MITM IPA-Mysuru Local Branch, JSS Pharmacy College, Mysuru & others note importance of Healthy Women –Healthy Society: Our ...

Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025: Basel Monday, October 20, 2025, 15:30 Hrs [ ...

Our Bureau, Bengaluru Monday, October 20, 2025, 15:20 Hrs [IST] Biocon Biologics, a global leader in biosimilars and the world ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Qure.ai launches AI-powered paediatric TB screening tool to extend proactive reach from birth to 15 years: Our Bureau, Bengaluru Monday, October 20, 2025, 14:30 Hrs [IST] Qure.ai, ...

SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...

ICICI Bank pledges Rs. 625 crore to set up radiation therapy facilities at Tata Memorial Centre, Navi Mumbai: Our Bureau, Mumbai Monday, October 20, 2025, 13:45 Hrs [IST] ICICI Ba ...

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event ...